The Relationship between Fibroblast Growth Factor Receptor Type 2 and other Indicators of Breast Cancer

Document Type : Original Article


1 Department of Pathology, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

2 Department of Anatomy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.


Background and Objective: Nowadays the therapeutic methods are being shifted toward “targeted therapy” which means specific therapy against one expressed factor in cancerous tissue.  In recent years several indicators for evaluating the prognosis of breast cancer have been under investigation. One of these is fibroblast growth factor receptor (FGFR2). Fibroblast growth factors play multiple physiological roles and in some studies have been regarded as effective parameter in prognosis of breast cancer while it has not been the case in other studies.
Subjects and Methods: The effects of them are exerted via their receptors.A retrospective study was applied.
Immunohistochemical method was applied. Also, statistical analysis was done.
 Results: No statistical correlation between FGFR2 and tumor size, age, microscopic grade and auxiliary lymph node metastasis were found.
Conclusion: We did not find any correlation. It is suggested that the study be performed in larger scale and other parameters be included in the survey. Furthermore, such survey should be performed concerning other common cancers. Also, some pilot medicines must be assessed in a clinical trial.


1- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics.CA Cancer J Clin 2011Mar-Apr; 61(2): 69–90.
2- Wang N, Ma Q, Wang Y, Ma G, Zhai H. Cacy BP/SIP expression is involved in the clinical progression of breast cancer. World J Surg 2010Nov; 34(1): 2545–52.
3-Olopade OI, Grushko TA, Nanda R, Hou D. Advances in breast cancer: Pathways to personalized medicine. Clin Cancer Res 2008; 14: 7988–99.
4-Dickson C, Spencer-Dene B, Dillon C, Fantl V. Tyrosine kinasesignalling in breast cancer: fibroblast growth factors and their receptors. Breast Cancer Res 2000: 2: 191–6.
5- Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, "et al". Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007; 447:1087–93.
6-Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE, "et al". A genome-wide association study identifies alleles in FGFR2 ssociated with risk of sporadic postmenopausal breast cancer. Nat Genet 2007Jul; 39(7): 870–4.
7-MartinAJ, GrantA, Ashfield AM, Palmer CN, Baker L, Quinlan PR, "et al". FGFR2 protein expression in breast cancer:nuclearlocalisation and correlation with patient genotype. BMC Research Notes 2011Mar, 4(72): 1-7.
8-Tannheimer SL, Rehemtulla A, Ethier SP. Characterization of fibroblast growth factor receptor 2 overexpression in the human breast cancer cell line SUM-52PE. Breast Cancer Res 2000May; 2(4): 311-20.

9-Sun S, Jiang Y, Zhang G, Song H, Zhang X, Zhang Y, "et al". Increased expression of fibroblastic growth factor receptor 2 is correlated with poor prognosis in patients with breast cancer. J Surg Oncol 2012 Jun; 105(8): 773–9.